FDA nod to Johnson & Johnson’s AKEEGA for aggressive prostate cancer
Patients with BRCA mutations often face aggressive disease and poor prognosis
Patients with BRCA mutations often face aggressive disease and poor prognosis
Convenient subcutaneous option has potential to reach more patients with same clinical benefits as Saphnelo IV infusion
Hansoh Pharma will receive an upfront payment in the low double-digit millions
Patient enrolment has been completed in Cynata's Phase 2 clinical trial of CYP-001 in acute graft versus host disease
India plays a critical role in Bristol Myers Squibb’s global strategy
Imsidolimab, an IgG4 IL-36 receptor antagonist, works by inhibiting IL-36 receptor signaling, directly addressing the deficiency in the IL-36RA regulator common in GPP patients
The approval of Nuzolvence (zoliflodacin) follows a collaborative development effort with the Global Antibiotic Research and Development Partnership
Ryght AI tackles these hurdles with its AI Site Twin platform
Subscribe To Our Newsletter & Stay Updated